Treace Medical Concepts, Inc. (TMCI) has a negative trailing P/E of -1.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -65.30%.
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -306.3 | 0.00 | 413.24 | 33.14 | - |
| 2020 | -356.1 | 22.78 | 1,683.33 | 22.77 | - |
| 2021 | -49.1 | -0.14 | 10.85 | 10.70 | - |
| 2022 | -29.7 | -0.29 | 21.00 | 8.96 | - |
| 2023 | -15.7 | -3.02 | 5.62 | 4.15 | - |
| 2024 | -8.3 | -0.75 | 4.09 | 2.21 | - |
| 2025 | -2.6 | -0.79 | 1.77 | 0.73 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.10 | $39.42M | $-5.11M | -13% |
| 2020 | $-0.13 | $57.37M | $-6.45M | -11.2% |
| 2021 | $-0.45 | $94.42M | $-24.61M | -26.1% |
| 2022 | $-0.86 | $141.84M | $-47.3M | -33.3% |
| 2023 | $-0.81 | $187.12M | $-49.53M | -26.5% |
| 2024 | $-0.90 | $209.36M | $-55.74M | -26.6% |
| 2025 | $-0.93 | $212.69M | $-59M | -27.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.91 | $-1.01 – $-0.74 | $205.69M | $205.22M – $205.97M | 3 |
| 2027 | $-0.84 | $-0.97 – $-0.66 | $222.59M | $219.31M – $225.93M | 3 |
| 2028 | $-0.97 | $-1.01 – $-0.95 | $225M | $224.92M – $225.08M | 1 |
